BioSpace News Archive

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the three-month period ended March 31, 2020.

SIWA Therapeutics, a Chicago-based, pre-clinical biopharmaceutical company, announced today that it is testing the ability of its humanized monoclonal antibody, SIWA 318H (the SIWA “mAb”) to directly target virally infected cells, including specifically, COVID-19.

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the protocol for the first trial from its clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) has been designated as “safe to proceed” by the US Food and Drug Administration (FDA).

BGI Genomics announced today that its subsidiary BGI Americas Corporation has received authorization under Interim Order from Health Canada to supply its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 in the Canadian market.

The Neuromuscular Disease Foundation (NDF) will launch its annual Symposium on GNE Myopathy Speaker Series on Friday, May 8th, albeit in a much different format than in previous years.

Cigna is launching its new COVID-19 Customer Protection Program to further safeguard its customers from unexpected costs for COVID-19 care through “surprise” or “balance” bills from out-of-network health care providers.